Watch-and-wait and immunotherapy after treatment for GI cancers
Part of Cancer, Digestive system clinical trials.
This trial looks at whether people with certain types of colorectal or other gastrointestinal cancers can avoid or delay surgery and instead be monitored closely (watch-and-wait) after receiving immunotherapy. It aims to see if this approach can keep the cancer from coming back while improving quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a gastrointestinal cancer (like colorectal, stomach, or esophageal) with certain genetic markers called MSI-H, dMMR, or POLE mutation.
- Your cancer is initially considered surgically removable and has not spread to distant parts of the body.
- You have received immunotherapy before, or are willing to receive it, and your tumor response is being evaluated by the study team.
- You are generally in good health (able to do daily activities) and have no major kidney problems.
- You have not had radiation therapy to the pelvic area, and you can have an MRI if needed.
- You do not have any other recent cancers (except certain types like skin or breast), no serious blood clots in the past 6 months, and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at whether people with gastrointestinal cancers who respond well to targeted or immunotherapy can safely avoid surgery and keep their organs. It aims to see if close monitoring and follow-up instead of surgery is a good option.
This trial tests whether using immune checkpoint inhibitors alone (like checkpoint blockade drugs) can help people with certain gastric or colon cancers avoid surgery. It's for patients whose tumors have a specific genetic feature called dMMR/MSI-H and haven't spread to other parts of the body.
This trial tests if adding immunotherapy to standard chemotherapy and radiation before surgery helps shrink high-risk rectal cancer and prevent it from coming back. You may be a good fit if you have a specific type of advanced rectal cancer that hasn't spread to other parts of your body.
This study looks at whether some patients with early-stage stomach, colon, or rectal cancers that are mismatch repair-deficient (a genetic feature making them more likely to respond to immunotherapy) can safely avoid surgery and instead be monitored closely after treatment with immunotherapy. It aims to confirm if this watch-and-wait approach is as effective and helps patients avoid major operations.
This trial looks at whether some patients with gastrointestinal cancers that have specific genetic markers can safely avoid surgery after immunotherapy, or have a less invasive procedure, instead of the standard radical surgery. It aims to see which approach is safer and more effective.
This trial tests giving immunotherapy (a drug that boosts your immune system to fight cancer) with or without radiation before surgery for colorectal cancer that is MSI-High or dMMR. It aims to see if this approach can shrink tumors and improve outcomes.
Hear when a new Gastrointestinal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.